Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): Results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005

Susana Rives, Jesús Estella, Pedro Gómez, Mónica López-Duarte, Purificación García de Miguel, Amparo Verdeguer, Maria José Moreno, José Luis Vivanco, José Miguel Couselo, Rafael Fernández-Delgado, Marisol Maldonado, María Tasso, Blanca López-Ibor, Francisco Lendínez, Ricardo López-Almaraz, Javier Uriz, Montserrat Melo, Ana Fernández-Teijeiro, Isidoro Rodríguez, Isabel Badell

Research output: Contribution to journalArticleResearchpeer-review

41 Citations (Scopus)

Abstract

Philadelphia-chromosome acute lymphoblastic leukaemia (Ph+ ALL) is a subgroup of ALL with very high risk of treatment failure. We report here the results of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP/SHOP) in paediatric Ph+ ALL treated with intermediate-dose imatinib concurrent with intensive chemotherapy. The toxicities and outcome of these patients were compared with historical controls not receiving imatinib. Patients with Ph+ ALL aged 1-18years were enrolled in three consecutive ALL/SHOP trials (SHOP-94/SHOP-99/SHOP-2005). In the SHOP-2005 trial, imatinib (260mg/m2 per day) was given on day-15 of induction. Allogeneic haematopoietic stem-cell transplantation (HSCT) from a matched related or unrelated donor was scheduled in first complete remission (CR1). Forty-three patients were evaluable (22 boys, median age 6.8years, range, 1.2-15). Sixteen received imatinib whereas 27 received similar chemotherapy without imatinib. Seventeen of 27 and 15 of 16 patients in the non-imatinib and imatinib cohort, respectively, underwent HSCT in CR1. With a median follow-up of 109 and 39months for the non-imatinib and imatinib cohorts, the 3-year event-free survival (EFS) was 29.6% and 78.7%, respectively (P=0.01). These results show that, compared to historical controls, intermediate dose of imatinib given concomitantly with chemotherapy and followed by allogeneic HSCT markedly improved early EFS in paediatric Ph+ ALL. © 2011 Blackwell Publishing Ltd.
Original languageEnglish
Pages (from-to)600-611
JournalBritish Journal of Haematology
Volume154
Issue number5
DOIs
Publication statusPublished - 1 Sep 2011

Keywords

  • BCR-ABL1
  • Children
  • Imatinib
  • Philadelphia-chromosome acute lymphoblastic leukaemia
  • Stem cell transplantation

Fingerprint Dive into the research topics of 'Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): Results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005'. Together they form a unique fingerprint.

Cite this